Dbv Technologies (DBV.PA) Stock Price
Dbv Technologies Price
Over the last 14 years Dbv Technologies grew revenue by 6.5% annually, reaching 4.15 M USD. For Dbv Technologies, the net margin of -2,749.3% is down versus -1,416.0% a few years ago. The consensus 12-month price target for Dbv Technologies is 6.31 USD, about 216.9% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Dbv Technologies stock price
Dbv Technologies business model & stock analysis
Frequently asked questions about Dbv Technologies
DBV Technologies SA's business model focuses on developing innovative products for the diagnosis and treatment of food allergies. The company specializes in creating safe and personalized immune therapies through its proprietary Epicutaneous Immunotherapy (EPIT) platform. By leveraging EPIT, DBV Technologies aims to address the unmet medical needs of patients with food allergies, especially peanut allergies. With a strong commitment to scientific research and collaboration, DBV Technologies strives to develop effective and convenient therapies to improve the lives of individuals suffering from allergies.
DBV Technologies SA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of DBV Technologies SA in the market include companies such as Aimmune Therapeutics, Allergan plc, and Stallergenes Greer. DBV Technologies SA competes with these companies in the field of healthcare and specifically in the development and commercialization of innovative therapies for allergies. DBV Technologies SA aims to differentiate itself in the market through its unique Viaskin technology that provides non-invasive and patient-friendly treatment options.
DBV Technologies SA is a leading biopharmaceutical company that specializes in the development of novel treatments for food allergies. Founded in 2002 and headquartered in Montrouge, France, DBV Technologies has garnered global recognition for its innovative Viaskin® platform, which aims to address the unmet medical needs of individuals with severe allergies. The company has made significant strides in advancing immunotherapy solutions, particularly for peanut and milk allergies. With its strong commitment to improving patients' quality of life, DBV Technologies continues to explore groundbreaking therapies and collaborate with healthcare professionals, researchers, and regulatory agencies worldwide.
DBV Technologies SA, a renowned biopharmaceutical company, has achieved several significant milestones. Notably, the company's innovative product Viaskin Peanut has shown promising potential in the treatment of peanut allergies. Furthermore, DBV Technologies SA has successfully conducted various clinical trials, demonstrating the safety and efficacy of their technology. The company has also received regulatory designations such as Fast Track designation from the U.S. FDA, recognizing the urgent need for their peanut allergy treatment. DBV Technologies SA continues to make strides in research and development, aiming to address unmet needs in the field of immunotherapy and improve the lives of patients worldwide.
DBV Technologies SA is primarily present in several countries and regions across the globe. The company has a significant presence in Europe, including France, where it is headquartered. Additionally, DBV Technologies SA has operations and key market presence in other European countries such as Germany, Italy, and the United Kingdom. The company also focuses on expanding its reach in North America, with a particular emphasis on the United States. Furthermore, DBV Technologies SA has been actively exploring opportunities in emerging markets, aiming to extend its presence to regions like Asia and the Middle East.
DBV Technologies SA represents values of innovation, dedication, and patient care. As a biopharmaceutical company, DBV Technologies is committed to developing groundbreaking treatments for severe food allergies. With a focus on immunotherapy, the company aims to transform the lives of patients by providing safe and effective solutions. DBV Technologies believes in collaboration, working hand in hand with the scientific community and healthcare professionals to advance treatments in the field. Emphasizing research and development, DBV Technologies is driven by its corporate philosophy to improve the quality of life for individuals affected by food allergies.
Analysts currently set an average price target of 6.71 USD for the Dbv Technologies stock (median: 6.31 USD), implying +236.6 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Dbv Technologies stock: 6 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Dbv Technologies to generate revenue of 3.54 M USD and earnings per share of -0.51 USD.
Converted at the current exchange rate, the Dbv Technologies share trades at 1.78 EUR (1.99 USD).
The Dbv Technologies share (DBV.PA) is listed on 6 stock exchanges, including: London (0QAJ.L), Frankfurt (DBV.F), München (DBV.MU), Düsseldorf (DBV.DU), Paris (DBV.PA).
DBV Technologies SA is a biopharmaceutical company specializing in the development and commercialization of therapies for the treatment of food allergies. The company's business model focuses on three main areas: research and development, registration and market introduction, and manufacturing and distribution. DBV Technologies' research and development department focuses on the discovery and development of therapies for the treatment of food allergies. The company has focused on the development of its Viaskin® technology platform, which enables the administration of allergens through the skin. This technology platform has the potential to achieve a breakthrough in the treatment of food allergies by allowing precise control of allergen administration. The registration and market introduction department of DBV Technologies focuses on obtaining approval for therapies for the treatment of food allergies and bringing these therapies to market. The company works closely with regulatory authorities in the United States and Europe to ensure that its therapies meet standards and are approved in a timely manner. The manufacturing and distribution department of DBV Technologies is responsible for producing and distributing therapies for the treatment of food allergies. The company has a production facility in France that is capable of large-scale production of its Viaskin products. DBV Technologies' flagship product is Viaskin Peanut, which is developed for the treatment of peanut allergies. The company has also conducted clinical studies to use its Viaskin technology platform for the treatment of milk allergies, egg allergies, and other food allergies. DBV Technologies aims to achieve a leading position in the food allergy market. It is expected to be driven by the growing need to create more effective treatment options for the millions of people worldwide affected by food allergies. With its Viaskin technology platform and flagship product Viaskin Peanut, the company is well positioned to succeed in this market. The company has also entered into partnerships with other companies to utilize its Viaskin technology platform. In 2017, the company entered into a partnership with Nestlé Health Science to develop a novel form of gastroenterological diagnosis. In summary, DBV Technologies SA is a biopharmaceutical company specializing in the development and commercialization of therapies for the treatment of food allergies. The company's business model focuses on research and development, registration and market introduction, and manufacturing and distribution. With its Viaskin technology platform and flagship product Viaskin Peanut, the company is well positioned to achieve a leading position in the food allergy market.
The expected revenue of Dbv Technologies is 3.54 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Dbv Technologies is -48.99 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Dbv Technologies is currently -3.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dbv Technologies stock.
The price-to-sales ratio (P/S) of Dbv Technologies is currently 54.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Dbv Technologies stock.
The Eulerpool Quality Score for Dbv Technologies is 2/10.
The ISIN of Dbv Technologies is FR0010417345. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Dbv Technologies is A1JWB7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Dbv Technologies is DBV.PA. The ticker symbol is used to trade Dbv Technologies shares on the stock exchange.
Dbv Technologies stock
Dbv Technologies Peer Group
Dbv Technologies Ticker
Dbv Technologies FIGI
All fundamentals and in-depth analysis of Dbv Technologies
Our stock analysis for Dbv Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dbv Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.